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A B S T R A C T   
Concerns that the phytoestrogens (isoflavones) in soy may feminize men continue to be raised. Several studies 
and case-reports describing feminizing effects including lowering testosterone levels and raising estrogen levels 
in men have been published. For this reason, the clinical data were meta-analyzed to determine whether soy or 
isoflavone intake affects total testosterone (TT), free testosterone (FT), estradiol (E2), estrone (E1), and sex 
hormone binding globulin (SHBG). PubMed and CAB Abstracts databases were searched between 2010 and April 
2020, with use of controlled vocabulary specific to the databases. Peer-reviewed studies published in English 
were selected if (1) adult men consumed soyfoods, soy protein, or isoflavone extracts (from soy or red clover) and 
[2] circulating TT, FT, SHBG, E2 or E1 was assessed. Data were extracted by two independent reviewers. With 
one exception, studies included in a 2010 meta-analysis were included in the current analysis. A total of 41 
studies were included in the analyses. TT and FT levels were measured in 1753 and 752 men, respectively; E2 and 
E1 levels were measured in 1000 and 239 men, respectively and SHBG was measured in 967 men. Regardless of 
the statistical model, no significant effects of soy protein or isoflavone intake on any of the outcomes measured 
were found. Sub-analysis of the data according to isoflavone dose and study duration also showed no effect. This 
updated and expanded meta-analysis indicates that regardless of dose and study duration, neither soy protein nor 
isoflavone exposure affects TT, FT, E2 or E1 levels in men.   
1. Introduction 
For centuries foods made from soybeans, such as tofu and miso, have 
played an important role in the diets of many Asian countries [1,2]. 
Much more recently, soyfoods have become popular in many non-Asian 
countries because of their purported nutritional and health benefits and 
the increased interest in plant-based diets and plant protein [3–7]. In 
addition to the traditional Asian soyfoods, soy protein can be incorpo-
rated into the diet via supplementation with and/or by consuming foods 
containing soy protein ingredients, namely soy flour, soy protein 
concentrate (SPC) and soy protein isolate (SPI). On a moisture free basis 
these products are approximately 50, 65 and 90 % protein, respectively 
[8]. 
Much of the soy-related health research published over the past 3 
decades has taken place because among commonly consumed foods, the 
soybean is a uniquely rich source of isoflavones [9,10]. Mean isoflavone 
intake in Japan among older adults ranges from approximately 
30–50 mg/d [11,12] whereas per capita isoflavone intake in the United 
States [13] and Europe [14] is <3 mg/d. The three isoflavones, genis-
tein, daidzein and glycitein and their respective glycosides, comprise 
approximately 50, 40 and 10 % of the total soybean isoflavones content, 
respectively [15]. Each gram of soy protein in traditional soyfoods is 
associated with approximately 3.5 mg isoflavones (expressed as the 
aglycone equivalent weight) [11]. In contrast, much of the isoflavone 
content is lost in the production of SPI and SPC, although the degree of 
loss depends upon the method of manufacture [15,16]. Isoflavone 
values in this manuscript refer to the aglycone equivalent weight. 
Isoflavones have a chemical structure similar to the hormone 
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estrogen which allows them to bind to both estrogen receptors (ER) – 
ERα and ERβ [17,18], and to exert estrogen-like effects under certain 
experimental conditions. For this reason, they are commonly classified 
as phytoestrogens. Circulating levels of isoflavones in response to the 
ingestion of approximately two servings of traditional soyfoods are three 
orders of magnitude higher than estrogen [19]. However, isoflavones 
differ from estrogen at the molecular level in that they preferentially 
bind to and activate ERβ in comparison to ERα whereas estrogen has 
equal affinity for both receptors [20–23]. This difference in binding 
preference is important because the two ERs have different tissue dis-
tributions and, when activated, can exert different and sometimes 
opposite physiological effects [24,25]. The preference of isoflavones for 
ERβ is the primary reason that isoflavones are seen as capable of having 
tissue-selective effects and the reason they are often classified as selec-
tive estrogen receptor modulators (SERMs) [26–30]. 
Isoflavones have been rigorously investigated over the past 30 years 
for a number of potential health benefits in both men and women 
[31–37]. However, isoflavones are not without controversy as there is 
concern that isoflavones feminize men. This concern, which coincided 
with the rising apprehension that environmental estrogens play a role in 
the declining sperm count occurring among men worldwide [38–40], 
has some support from animal studies [41,42]. 
Some clinical studies have also reported decreases in testosterone 
levels in response to soy consumption [43,44]. In addition, one 
case-report described a 60-year-old male who developed gynecomastia 
allegedly as a result of his soy intake [45] and a small case control study 
found that soy intake was associated with lower sperm concentration 
among male partners in subfertile couples who presented for semen 
analyses to the Massachusetts General Hospital Fertility Center [46]. 
As a result of feminization concerns, in 2010, three of us co-authored 
a meta-analysis of clinical studies that examined the effects of isoflavone 
exposure via supplements and soyfoods on circulating levels of total TT, 
FT and SHBG [47]. This analysis found no statistically significant effects 
of soy protein or isoflavone intake on any of the outcomes assessed. That 
same year also saw the publication of a narrative review which found 
soy/isoflavones had no effect on estrogen levels in men or other end-
points related to feminization [48]. 
Nevertheless, reports of soy exerting estrogenic or feminizing effects 
subsequent to the 2010 meta-analysis [47] and narrative review [48] 
have been published. For example, a case-report by Siepman et al. [49] 
described a 19-year-old vegan who developed hypogonadism and 
erectile dysfunction allegedly as a result of his soy consumption. It is 
notable that the man described in this case-report and in the previously 
cited one [45], consumed an estimated 360 mg/d isoflavones, which is 
approximately 9 times the typical intake of older native Japanese men 
[11]. Also, in young resistance-trained men supplementation with soy 
protein resulted in lower testosterone levels shortly after exercise per-
formance in comparison to whey protein and carbohydrate supple-
mentation [50]. Observational studies have also reported associations 
between isoflavone exposure and decreased sperm concentration and/or 
poor semen quality [51–53]. 
Given the conflicting reports and the number of relevant studies 
published within the past decade, we have updated and expanded the 
2010 meta-analysis [47]. In addition to including levels of SHBG, TT and 
FT, levels of E2 and E1 were also meta-analyzed since no previous sta-
tistical analysis of the effect of soy on these latter two hormones has been 
published. 
2. Materials and methods 
2.1. Study identification 
Intervention trials were identified on PubMed (National Library of 
Medicine, Bethesda, MD), with the search dates of 2010 to April 10, 
2020. The keywords used were soybeans, soy, soyfoods, soy foods, iso-
flavones, genistein, daidzein, phytoestrogens, red clover, androgen, 
estradiol, estrogen, estrone, hormones, testosterone, and sex hormone- 
binding globulin. Peer-reviewed studies published in English were 
selected based upon two criteria: 1) if adult men consumed soyfoods, soy 
protein isolate (SPI), soy protein concentrate (SPC) or isoflavone ex-
tracts (from soy or red clover) and 2) if studies assessed circulating TT, 
FT, E2, E1 or SHBG. Two independent reviewers extracted data. Isofla-
vone exposure was extracted directly from studies. With one exception, 
studies published before 2010 included in a previously published meta- 
analysis were included in the current analysis [47]. Clinical trials (par-
allel or crossover) and single-group studies were included. Data from 
single-group studies were analyzed separately from two-group com-
parisons in the manner described below. A total of 141 articles were 
examined. Reports that did not match the selection criteria were 
excluded (n = 101) from the analysis. 
2.2. Data analysis 
Data were analyzed using Review Manage (RevMan) version 5.3 
(Copenhagen: The Nordic Cochrane Centre, Cochrane Collaboration). 
Data were extracted or calculated in accordance with the Cochrane 
Collaboration. Missing standard deviations (SD) were generated using 
available data from the study (standard error [SE] or confidence interval 
[CI]) or imputed using evidence from similar studies. SD of change 
(when not given) was calculated using baseline and final SD as suggested 
by Cochrane. Two analytical comparisons were made: 1) effect sizes 
(standardized mean difference, SMD) were calculated by comparing the 
change between baseline and end values in active treatment arms with 
the change between baseline and end values in the control arm, of all 
parallel (controlled) and crossover trials (analysis A); and 2) effect size 
was calculated for the difference between baseline and end values in the 
treatment arm only of parallel, crossover and single-group studies 
(analysis B). 
The SMD was calculated for both comparisons, for the five outcomes 
(hormones of interest) measured (TT, TF, SHBG, E2 and E1), thus 10 
models were calculated in total. A random effects model was used to 
calculate the SMD difference and the 95 % CI, to account for differences 
in measurement units and techniques. 
The data were also analyzed using the statistical models A and B 
described above to determine whether isoflavone exposure duration 
(≤12 weeks vs >12 weeks) or dose (<75 mg/d vs ≥75 mg/d) affected 
outcomes. Heterogeneity among studies was assessed using I2 and broad 
cutoff points of <40 %, 40%–60%, 61%–90% and 100 % were used to 
establish the importance of heterogeneity (non-important to consider-
able). Finally, funnel plots were used to assess publication bias, and the 
effect of over influential studies on model change was examined by 
removing studies one at a time. 
3. Results 
Based on the established criteria a total of 41 studies were included 
in the analyses [37,43,44,54–91]. Of the 41 studies, 20 utilized a par-
allel design (controlled), eight a crossover design and 15 single arm or 
parallel arms designs. Two studies identified by the literature search 
were excluded from the analysis because of their short duration as one 
measured TT and SHBG over a 60-minute period following a bout of 
resistance exercise [50], and one measured E2, TT and FT after one week 
exposure [92]. In the latter study, which did not find a significant effect 
on hormone levels, it was not possible to determine the soy protein or 
isoflavone dose based on the description of the intervention product 
(900 g soybeans) [92]. In addition, a study by Lephart [93] was 
excluded from analysis because the intervention supplement was 
comprised of equol, which is a bacterially-derived metabolite of daid-
zein that is not found in soybeans. Also, a study by Grainger et al. [94] 
was not included in the current analysis despite being included in the 
2010 meta-analysis [47] because the original data, which was not 
published in the paper, is no longer accessible. 
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Some studies included soy groups that were excluded from the an-
alyses due to the addition of other potentially bioactive ingredients to 
the test product. This included soy bread with linseed [54], soymilk 
fortified with stanols [95] and a mixture of soy and whey [60]. Selected 
details of studies included in the meta-analysis are shown in Table 1. 
TT and FT levels were measured in 1753 and 752 men, respectively; 
E2 and E1 levels were measured in 1000 and 239 men, respectively and 
SHBG was measured in 967 men. The youngest men were aged 18 years 
[55,84] and the oldest participants were aged 81 years [77]. Several 
studies included more than one experimental arm, for example a SPC 
arm and a SPI arm, thus the total number of groups included in analyses 
exceeded the total number of studies. Some studies involved multiple 
quantities of soy, or soy in different forms. For example, both Swart et al. 
[70] and Hamilton- Reeves et al. [57] included a SPI with added iso-
flavones group and a SPI alone group. Kalman et al. [60] included a SPI 
group and a SPC group and the study by Kumar et al. [63] included 3 
groups who consumed supplements providing different amounts of 
isoflavones. Most studies that did not intervene with supplements used 
SPI or SPC, several studies used other forms including red clover [68, 
80], soymilk/yogurt [66,76], tofu [75] or soybeans [92]. 
3.1. Effect of soy and isoflavone exposure on circulating reproductive 
hormone concentrations 
As shown in Table 2, there were no significant effects of soy or iso-
flavone exposure on any of the hormones considered regardless of 
whether the data were analyzed using statistical approach A) compari-
son of change in the treatment versus the control arms of parallel/ 
controlled and crossover trials or B) change over time in all active arms. 
Subanalysis revealed that neither study duration (≤12 weeks vs >12 
weeks) (Table 3) nor dose (<75 mg/d vs ≥75 mg/d) (Table 4) affected 
the impact of isoflavone exposure on hormone concentrations although 
in the case of statistical model A (change in treatment arm compared 
with change in control arm) in several cases there were insufficient 
studies (N < 3) to conduct an analysis. 
3.2. Publication bias and over-influential studies 
No publication bias was noted in the funnel plots (data not shown). 
There were no over- influential studies in either analysis method for TT, 
FT or SHBG when studies were removed one at a time and the models 
then re-estimated. In analysis A (change in treatment versus change in 
control) for E2, removal of the 2010 study by Kumar et al. [63] had the 
largest influence, although the model still remained non-significant 
(p = 0.06). In the study by Haun et al. [59], the control group experi-
enced a drop in E2 that was more than double the drop in the inter-
vention arm, but removal of this study had little to no influence on the 
effect size. In fact, in the 13 studies that measured E2, there was a drop 
in the control group in all but two studies [63,70]. However, as can be 
seen from analysis B (Table 2), there is little actual change over time in 
the active arms (p = 0.43) 
In the E1 analysis, removal of the study by Nagata et al. [66] from 
analysis B had the largest influence, resulting in a relatively large change 
in the SMD as it changed from 0.40 [-0.27, 01.07] to 0.62 [-0.03, 1.27], 
although the effect remained non-significant (p = 0.06). Given the small 
number of groups in this analysis, removal of single studies can have a 
large influence. As was the case for E2, there is little actual change over 
time in the active arms (model B). 
4. Discussion 
The results of this meta-analysis confirm the findings of a meta- 
analysis published in 2010 that found neither soy nor isoflavone 
intake affects total or bioavailable circulating testosterone concentra-
tions in men [47]. Given that the current analysis includes 41 studies 
(TT) and 1753 men (versus 31 studies and 939 men in the 2010 analysis 
[47]), it is unlikely that additional research will alter this conclusion, 
especially when considering the low heterogeneity (model B, change 
over time; I2, 30 %) among studies. The lack of effect on TT and FT held 
when the data were sub-analyzed according to study duration (≤12 
weeks vs >12 weeks) and isoflavone dose (≤75 mg/d vs >75 mg/d). 
Evidence indicates that testosterone levels can change very quickly 
so it is unlikely that longer studies would produce different results. For 
example, in healthy male volunteers, testosterone levels began to 
decrease from baseline values after 72 h of ethanol ingestion and 
reached levels similar than those of alcoholic men after 30 days [96]. 
Importantly, none of the four longer-term studies (≥12 months) in this 
analysis found a statistically significant effect on testosterone levels [64, 
65,67,72]. 
Regarding dose, mean isoflavone intake of older native Japanese 
men ranges from about 30–50 mg/d [11,12,97]. Relatively few Asians 
(<10 %) consume more than 75 mg/d, which is the amount provided by 
approximately three servings of traditional soyfoods. A serving being 
one cup (240 mL) of soymilk, ½ cup (~85 g) of tofu or one ounce (28 g) 
of soynuts. Thus, by Asian standards, the cutoff of 75 mg/d would cover 
a high intake of soyfoods. Whether greater isoflavone exposure than can 
reasonably be achieved via the consumption of traditional soyfoods 
impacts testosterone levels is difficult to assess, but the existing evidence 
suggesting that it does is unimpressive. 
In eight studies included in this analysis men consumed >100 mg/ 
d isoflavones [44,54,74,79,80,85,88]. Of these, Gardner-Thorpe et al. 
[44] reported an approximate 5% decrease in TT whereas Pendleton 
et al. [85] reported an approximate 6% decrease in FT, but no effect on 
TT. In the former study, the decrease in TT was in comparison to base-
line values as data for the control group were not reported. van Veld-
huizen et al. [88] reported a change in TT from 5.004 ng/mL at baseline 
to 3.175 ng/mL (no statistics reported) among 11 prostate cancer pa-
tients who consumed between 112 and 224 mg/d isoflavones. This study 
did not include a control group. In contrast to these three studies, no 
effects on TT and/or FT were noted by several other investigators [54, 
80,89–91]. Finally, among nine men with histological proven prostate 
cancer whose prostate specific antigen (PSA) levels decreased in 
response to 900 mg/d isoflavones, deVere White et al. [79] reported that 
one patient had a reduced TT level at three months but five others had 
increased levels at 6 months. 
We did not examine the effects of isoflavone exposure on circulating 
levels of dihydrotestosterone (DHT), which is the 5α-reduced metabolite 
of testosterone that is principally converted from its parent hormone in 
target organs such as prostate, skin, and liver [98]. The reason is that as 
noted by Swerdloff et al. [98] and as first concluded by Horton [99], 
blood levels of DHT “provide only a hint of tissue levels as DHT should 
be regarded as a paracrine hormone formed and acting primarily within 
target tissues.” The impact of isoflavone exposure on DHT has been 
studied to a much lesser degree than has testosterone, but the evidence 
indicates that like testosterone, there is no effect on this testosterone 
metabolite [44,54,57,68,74,75,89,90]. 
Three studies did find changes in DHT in response to isoflavone 
intake [73,77,82], two of which found decreases and one of which, that 
intervened with isoflavones derived from red clover, found an increase 
[82]. In addition, a small study by Tanaka et al. [87] found isoflavones 
decreased DHT levels (also free testosterone levels) in equol-, but not 
equol-producers. Approximately 25 % of Westerners and 50 % of Asians 
host the intestinal bacteria that convert the isoflavone daidzein into 
equol, a conversion that some speculate will benefit individuals 
consuming isoflavones [100]. The finding by Tanaka et al. [87] is 
interesting because equol is able to specifically bind to 5α-DHT (to 
decrease negative androgen impact in the prostate) by sequestering 
5α-DHT from the androgen receptor, thus altering growth and physio-
logical hormone responses regulated by 5α-DHT [101,102]. However, in 
a small pilot study by Lephart et al. [93], no effect of equol supple-
mentation (12 mg/d) was found on serum DHT levels in 18 men with 
benign prostatic hyperplasia (BPH) although this study did find some 
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Table 1 
Description of the studies included in the meta-analysis.  
Author/year/ 
Location/(ref) 
Mean or median age 
(y) ± SD or range 














117 25 d T, SHBG 8 11 61 ± 5 
DiSilvestro/2006/ 




98 4 wk T Whey protein 42 10 
Deibert/2011/ 
Germany/(56) 
56 SPI 13 Healthy 27 NI 12 wk FT 
55 Usual diet 0 13 
Hamilton- Reeves 
/2007/USA/(57) 
68 ± 8 SPI 20 High risk for prostate 40 107 
6 mo T, FT, SHBG, 
E1, E2 
SPI 40 <6 
68 ± 5 
Milk protein isolate 
20 
cancer 40 0 68 ± 7 18 
Hamilton-Reeves 
/2013/USA/(58) 
62 ± 12 Capsules 42 
Prostate cancer 
0 51 
2− 6 wk T, FT, E2 Capsules 0 0 44 62 ± 7 
Haun/2018/USA/ 
(59) 
21 ± 2 SPC Whey 11 
Healthy 
39 32 
12 wk T, E2 
Carbohydrate 
26 1 9 
<1 1 21 ± 2 12 
21 ± 1 
Kalman/2007/USA/ 
(60) 
30 SPI 5 
Healthy 
30 29 
12 wk T, FT, E2 31 SPC 5 30 77 
30 1 29 Whey protein 5 
Kumar/2004/USA/ 
(61) 
71 ± 5 SPI 29 Prostate cancer 29 60 
12 wk 
T, FT, SHBG, 
E2 SPI 30 0 30  72 ± 5 
Kumar/2007/USA/ 
(62) 
72 ± 6 Capsules 22 Prostate cancer 0 48
a 
12 wk T, FT, SHBG, 
E2 0 0 Capsules 27 72 ± 6 
Kumar/2010/USA/ 
(63) 





4 wk FT, SHBG, E2 




59 ± 6 
59 ± 7 10 
Kumar/2020/(37) 
58.8 ± 7.5 




3− 6 wk 
TT, FT, E2, 
SHBG Capsules 0 0 35 
Li/2008/USA/(64) 60 ± 1 SPI 26 Prostate cancer 40 80 12 mo T 
Usual diet 0 0 14 63 ± 2 
Miyanaga/2012/ 
Japan/(65) 
66 Capsules 78 Rising prostate specific 
antigen 
0 36 
12 mo T, SHBG, E2 65 Capsules 0 0 80 
Nagata/2001/ 
Japan/(66) 
32 ± 8 Soymilk 17 
Healthy 13.40 55a 8 wk 
T, FT, SHBG, 
E1, E2 Usual diet 33 ± 8 17 
Ornish/2005/USA/ 
(67) 
65 ± 7 Tofu/SPI 43 Prostate cancer ~60 Not indicated 12 mo T 
0 Usual diet 0 67 ± 8 41  
Rannikko/(2006/ 
Finland/(68) 
64 ± 3 Red clover tablets 20 Prostate cancer 0 NI 2 wk T, FT, SHBG, 
E1, E2 0 64 ± 3 Tablets 20 
Reidy/(2016/USA/ 
(69) 





12 wk T 0 25 ± 1 Whey 18 
Swart/2019/ 
England/(70) 
52 SPI 85 Diabetes 15 66 
3 mo T, SHBG, E2 52 SPI 15 0 86  
Teede/2001/ 
Australia/(70) 
50− 75 SPI 48 Healthy 40 71
a0 12 wk T 
Casein 40  48 
Wong/2012/Hong 
Kong/(72) 
65 ± 9 Capsule Capsule 72 Benign prostatic 
hyperplasia 
0 40 12 mo T 
0 0 65 ± 9 74 
Cross-over studies 
Dillingham/2005/ 





T, FT, SHBG, 
E1, E2 
SPI 32 62 





2003/UK/(44) 35 ± 11 




T, SHBG, E1, 










6 wk T, E1, E2 








46 ± 8 Tofu 42 Healthy 35 Not indicated 4 wk T, SHBG, E2 
Lean meat 0 42  
Higashi/2001/ 




Not indicated 4 wk T, E2 Usual diet 0 14 
Kranse/2005/ 




6 wk T Tablets 0 0 
Maskarinec/2006/ 
USA/(78) 
58.7 ± 7.2 Soyfoods 23 Healthy NI ~69 12 wk T 
Usual diet  <5 23 
Schroder/2005/ 
Netherlands/(89) 
70 ± 7 Tablets 49 Prostate cancer or rising 
PSA 
0 0 10 wk T, SHBG 
Tablets 0 62.5 49 
Single or dual arm studies (no control) 
73.6 Capsules 52 Prostate cancer <1 900 6 mo T 
(continued on next page) 
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evidence that BPH symptoms were alleviated. Also, in contrast to the 
finding by Tanaka et al. [87], in a case-control study involving Japanese 
men with rising PSA levels, Miyanaga et al. [65] found that DHT levels 
did not differ between non-equol producers and equol producers. 
There were insufficient data upon which to determine whether equol 
per se, alters reproductive hormone levels. Most studies in this analysis 
did not determine equol producer status. Furthermore, even if more had, 
they would almost certainly be underpowered to detect a difference 
given the low prevalence of producers among non-Asian men. In addi-
tion to equol, there were insufficient data to evaluate the effects of 
isoflavone exposure on androgen receptor (AR) expression. Of note in 
this regard, Hamilton-Reeves et al. [57] found that AR expression in the 
Table 1 (continued ) 
Author/year/ 
Location/(ref) 
Mean or median age 
(y) ± SD or range 










32.25 SPI 12 Healthy 56 NI 12 wk T 
Fischer/2004/USA/ 
(90) 
68.9 ± 7.3 Tablets 20 Prostate cancer 0 300− 600 84 d T, FT 
Hussain/2003/ 
USA/(91) 
73 (55− 82) Tablets 39 Prostate cancer 0 200 5.5 mo T 
Jarred/2002/ 
Australia/(80) 
60 ± 7 Red clover 20 Prostate cancer 0 160 20 d T 
Kwan/(2010/ 
Canada/(81) 
78 Soymilk 29 Prostate cancer 12 65− 90 6 mo T 
Lewis/2002/New 
Zealand/(82) 
40− 53 Tablets, red clover 6 Healthy 0 40 3 wk T 
Mackey/2000/ 
Australia/(83) 
51.8 SPI 27 Healthy 28 65 12 wk T, SHBG 
Mitchell/2001/ 
Scotland/(84) 
18− 35 Tablets, red clover 11 Healthy 0 40 2 mo T, E2 
Pendleton/2008/ 
USA/(85) 
73 Soymilk 12 Prostate cancer NI 141 12 mo T 
Spentzos/2003/ 
USA/(86) 
71 SPI 18 Prostate cancer 34 68a 2 mo T, FT, E2 
Tanaka/2009/ 
Japan/(87) 




63 Tablets 11 Prostate cancer 0 112− 224 4 wk T  
a Converted to aglycone value. 
Table 2 
Effects of isoflavone exposure on reproductive hormone levels in men.  
Outcome/ 
statistical modela 
No of groups 
(subjects) 
Effect size SMD 
(95 % CI) 







20 (1241) − 0.06 [-0.29, 
0.17] 
0.59 72 
Change over time 
(active) 
42 (1101) 0.09 [-0.02, 
0.20] 
0.12 29 
Free (unbound) testosterone 
Treatment vs 
Control 
15 (724) 0.01[-0.33, 
0.32] 
0.98 76 
Change over time 
(active) 






18 (856) − 0.03 [-0.45. 
0.38] 
0.88 87 
Change over time 
(active) 






16 (835) 0.18 [-0.04, 
0.41] 
0.12 56 
Change over time 
(active) 






6 (220) 0.40 [-0.27, 
1.07] 
0.24 83 
Change over time 
(active) 
8 (184) 0.18 [-0.12, 
0.47] 
0.24 0  
a Model A: Treatment vs control is an analysis of the change (in the treatment 
arms vs the change in the control arms); model B: the change over time in the all 
active arms. SMD is standardized mean difference. 
Table 3 




≤12 weeks Studies (n, 





N = 15 (372; 372) 
SMD - 0.11 
[-0.43,0.20] Z = 0.69 
p = 0.49 
N = 5 (255; 242) SMD 
0.01 [-0.28,0.30] 
Z = 0.05 p = 0.96 
B 
N = 32 (821) SMD 
0.05 [-0.08, 0.19] 
Z = 0.76 p = 0.45 
N = 10 (360) SMD 
0.18 [-0.13,0.39] 




N = 14 (340; 342) 
SMD 0.03 [-0.31, 0.36] 
z = 0.16 p = 0.87 
Insufficient groups 
B 
N = 16 (410) SMD 
-0.32 [-0.23,0.16] 




N = 15 (312; 317) 
SMD 0.00 [-0.51,0.51] 
Z = 0.0 p = 0.99 
N = 3 (124; 103) SMD 
-0.21 (-0.97, 0.55) 
Z = 0.54 p = 0.59 
B 
N = 22 (546) SMD 
-0.03 [-0.20,0.14) 
Z = 0.38 p = 0.70 
N = 3 (124) SMD 0.06 
(-0.29, 0.41) Z = 0.33 
p = 0.74 
Estradiol 
A 
N = 14 (315; 322) 
SMD 0.21 (-0.04,0.48) 
Z = 1.5 p = 0.13 
Insufficient groups 
B 
N = 23 (530) SMD 
0.10 [-0.07, 0.26] 




N = 4 (7; 73) SMD 
0.24 [-0.64,1.13] 
Z = 0.54 p = 0.59 
Insufficient groups 
B 
N = 6 (142) SMD 0.15 
(-0.18,0.48) Z = 0.89, 
p = 0.37 
Insufficient groups  
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prostate was suppressed (~8%) in response to isoflavone intake. In 
future research it may be worth comparing isoflavones with other agents 
that inhibit AR expression to determine their potential in prostate cancer 
treatment. 
To our knowledge, the current meta-analysis is the first to examine 
the effects of soy intake and isoflavone exposure on estrogen levels in 
men. A meta-analysis published in 2009 found no effect on estrogen 
levels in pre- or postmenopausal women [103]. One year later, a 
narrative review based on nine studies concluded there was no effect of 
isoflavone exposure on estrogen levels in men [48]. These publications 
concur with the findings of the current analysis in that statistically sig-
nificant changes were not found for E2 or E1 [48]. There was only a 
moderate amount of heterogeneity (model A, I2 = 56 %) among the 16 
studies. Only eight studies evaluated E1. 
It should be emphasized that the lack of effect of soy intake and 
isoflavone exposure on these reproductive hormones in men does not 
necessarily mean that soy or isoflavone intake does not exert any hor-
monal effects. Isoflavones could exert biological effects independent of 
effects on hormone levels, such as by directly interacting with ERs and/ 
or the AR. However, clinically relevant endpoints can therefore also 
inform about the possible impact of soy related to the effects of repro-
ductive hormones. In this regard, it is notable that clinical studies show 
no effect of soy on sperm and semen parameters [84,104] and soy 
protein supplementation leads to similar gains in muscle mass and 
strength among men engaged in resistance exercise training as animal 
protein, including whey protein supplementation [105]. 
Finally, while the results of this meta-analysis are based on a large 
dataset it is important to acknowledge, as noted in the methods section, 
that it was necessary to make a number of assumptions when full data 
for the individual studies were not available. In addition, many of the 
trials did not indicate whether the isoflavone intervention dose was 
expressed in aglycone equivalent or glycoside weight. We attempted to 
ascertain the aglycone equivalent dose based on general knowledge of 
the intervention product, but uncertainty still existed in many cases. 
In conclusion, extensive clinical data published over the past two 
decades shows that in men neither soy nor isoflavone intake, even when 
exposure occurs for an extended period of time and exceeds typical 
Japanese intake, affects levels of total testosterone, free testosterone, 
estradiol or estrone. 
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